Two studies presented at the Society of Interventional Radiology s 37th Annual Scientific Meeting in San Francisco, USA (24–29 March 2012) highlight the clinical benefits of treatment with radiofrequency targeted vertebral augmentation therapy (RF-TVA) with the StabiliT Vertebral Augmentation System (DFine) to repair vertebral compression fractures resulting from instability due to osteoporosis or cancer.
Un nuevo fármaco llamado tenecteplasa podría ser más eficaz en el tratamiento de los accidentes cerebrovasculares (ACV) provocados por coágulos en los vasos sanguíneos grandes del cerebro que la terapia estándar actual, informan investigadores australianos.
Vall dHebron coordinará en España el mayor estudio sobre el uso de la hipotermia en el tratamiento del ictus Por Hospital Vall dHebron Publicada: 21/03/2012 Noticias de Neurologia , Noticias Marzo 2012 Hospital Vall dHebron Ver todas las noticias por Hospital Vall dHebron Vall d’Hebron coordinará en España el mayor estudio sobre el uso de la hipotermia en el tratamiento del ictus. Lanzamiento del proyecto EUROHYP-1
A subanalysis of the SAMMPRIS (Stenting vs. aggressive medical therapy for intracranial arterial stenosis) trial found that there were lower outcome events with aggressive medical management than with stenting, even in patients who had failed antithrombotic therapy, who are perceived as being at high-risk.
Makoto Negoro, professor, Fujita Health University, School of Medicine, Toyoake-Nagoya, Japan, tells NeuroNews that simulation-based training is beginning to receive great attention in surgery and endovascular intervention. He says the simulator, called EVE, which takes its initials from EndoVascular Evaluator, is able to analyse the process and the result of an intervention performed by a trainee.
La sesión, que se celebró este miércoles 14 de marzo, abarcó el desarrollo de esta técnica y su perfeccionamiento a lo largo de medio siglo.
Cinco destacados especialistas en Neurocirugía a nivel mundial se reúnen en Madrid con motivo del Curso en Técnicas avanzadas en Radiocirugía que organiza la Fundación Grupo IMO en colaboración Hospital Ruber Internacional.
The Food and Drug Administration (FDA) has given clearance to ev3 / Covidien for its Solitaire FR revascularisation device which is intended to restore blood flow to the brain in patients suffering acute ischaemic stroke by mechanically removing blood clots from blocked vessels.
Covidien announced that the Solitaire FR Revascularization device has been approved for investigational use in the IMS III (Interventional management of stroke) trial. The Solitaire FR device was approved by the IMS III executive committee in the thrombectomy arm of the trial and was included in a recently approved amendment submitted to the US Food and Drug Administration (FDA).
El Grupo IMO, pionero en España en Radiocirugía realiza el primer tratamiento con esta técnica en el Instituto Oncológico Cartuja.
On 8 February, The board of directors of Stryker announced that Stephen P MacMillan has resigned as chairman, president and CEO for family reasons, effective immediately. Curt Hartman, vice president and chief financial officer, has been named interim chief executive officer and William U Parfet, lead independent director, becomes non-executive chairman. The board has begun a search for a permanent successor to MacMillan and will consider both internal and external candidates.
An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented on 3 February at a late breaking trial session by Jeffrey L Saver, Stroke Center director, University of California, Los Angeles, (UCLA), USA, at the American Stroke Association’s International Stroke Conference 2012.
The risk of re-bleeding after intracranial hemorrhage did not increase when patients received early prophylaxis for venous thromboembolism (VTE), results of a retrospective review showed. Re-bleeding or hematoma expansion within 24 hours occurred in 5% to 6% of patients, irrespective of the timing of VTE prophylaxis.
On 2 February, at the Late-Breaking Science Session at the International Stroke Conference, the results of the TREVO study (Thrombectomy revascularization of large vessel occlusions in acute ischaemic stroke) were presented. TREVO is one of the first prospective, multicentre clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centres in Europe.
A new analysis from a two-year follow up of participants in the CREST (Carotid revascularization endarterectomy versus stenting) trial show that carotid artery stenting and carotid endarterectomy are equally effective at halting carotid restenosis in stroke prevention. Results of the analysis were detailed in a presentation at the American Stroke Association’s International Stroke Conference (%ew Orleans, USA, 1–3 February 2012).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos